These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20524720)

  • 1. The risk for significant creatine kinase elevation with statins.
    Stolcpart RS; Olson KL; Delate T; Rasmussen J; Rehring TF; Merenich JA
    Am J Cardiovasc Drugs; 2010; 10(3):187-92. PubMed ID: 20524720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential association between statin exposure and elevated levels of creatine kinase.
    Chan J; Hui RL; Levin E
    Ann Pharmacother; 2005 Oct; 39(10):1611-6. PubMed ID: 16160000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
    Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
    Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
    Glueck CJ; Rawal B; Khan NA; Yeramaneni S; Goldenberg N; Wang P
    Metabolism; 2009 Feb; 58(2):233-8. PubMed ID: 19154957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle toxicity with statins.
    Hedenmalm K; Alvan G; Ohagen P; Dahl ML
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):223-31. PubMed ID: 20014178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
    McClure DL; Valuck RJ; Glanz M; Murphy JR; Hokanson JE
    J Clin Epidemiol; 2007 Aug; 60(8):812-8. PubMed ID: 17606177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of statin dosing intensity on transaminase and creatine kinase.
    Dale KM; White CM; Henyan NN; Kluger J; Coleman CI
    Am J Med; 2007 Aug; 120(8):706-12. PubMed ID: 17679130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
    Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J
    Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin-related adverse events: a meta-analysis.
    Silva MA; Swanson AC; Gandhi PJ; Tataronis GR
    Clin Ther; 2006 Jan; 28(1):26-35. PubMed ID: 16490577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing statin-induced muscle toxicity in a lipid clinic.
    Blaier O; Lishner M; Elis A
    J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and cancer risk.
    Karp I; Behlouli H; Lelorier J; Pilote L
    Am J Med; 2008 Apr; 121(4):302-9. PubMed ID: 18374689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Creatine kinase increase under simvastatin--therapeutic consequences?].
    Rasche-Schürmann CC; Picksak G; Stichtenoth DO
    Med Monatsschr Pharm; 2008 Jan; 31(1):25-7. PubMed ID: 18522017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle symptoms associated with statins: a series of twenty patients.
    Soininen K; Niemi M; Kilkki E; Strandberg T; Kivistö KT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):51-4. PubMed ID: 16433891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction.
    Briguori C; Colombo A; Airoldi F; Violante A; Focaccio A; Balestrieri P; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Librera M; Bonizzoni E; Ricciardelli B
    Eur Heart J; 2004 Oct; 25(20):1822-8. PubMed ID: 15474697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
    Corrao G; Conti V; Merlino L; Catapano AL; Mancia G
    Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.
    Nichols GA; Koro CE
    Clin Ther; 2007 Aug; 29(8):1761-70. PubMed ID: 17919557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.
    Alberton M; Wu P; Druyts E; Briel M; Mills EJ
    QJM; 2012 Feb; 105(2):145-57. PubMed ID: 21920996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.